A phase I/II trial to evaluate the safety, feasibility and activity of salvage therapy consisting of the mTOR inhibitor Temsirolimus added to standard therapy of Rituximab and DHAP for the treatment of patients with relapsed or refractory diffuse large cell B-Cell lymphoma – the STORM trial

Peer Review reports

Original Submission
18 Aug 2012	Submitted	Original manuscript
19 Feb 2013	Reviewed	Reviewer Report - m christina cox
25 Feb 2013	Reviewed	Reviewer Report - Andres Forero
26 Feb 2013	Reviewed	Reviewer Report - Jehan Dupuis
3 Apr 2013	Author responded	Author comments - Mathias Witzens-Harig
Resubmission - Version 2
3 Apr 2013	Submitted	Manuscript version 2
Publishing
21 Jun 2013	Editorially accepted
25 Jun 2013	Article published	10.1186/1471-2407-13-308

Back to article page